PIRS Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing Anticalin class of biotherapeutics for patients with diseases in which there is high unmet medical needs.

$3.53
As of 06/18/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/02/2015
Outstanding shares:  63,303,219
Average volume:  28,738,359
Market cap:   $240,552,232
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    720795103
ISIN:        US7207951036
Sedol:      BTJRTY1
Valuation   (See tab for details)
PE ratio:   -5.91
PB ratio:   5.52
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy